COMMUNIQUÉS West-GlobeNewswire

Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation
28/09/2026
Binding term sheet with PsyLabs provides Psyence BioMed’s Texas subsidiary with exclusive U.S. development, supply and distribution rights to PsyLabs’ pharmaceutical-grade ibogaine, subject to a definitive agreement NEW [...]
BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer
28/09/2026
Preclinical data demonstrate prolonged KRAS target engagement and potent antitumor activity across multiple KRAS-mutant cancer models, supporting the continued advancement of BH-501284 toward an IND submission in Q1 [...]
BrewDog Builds Momentum for Next Growth Chapter with Expanded Senior Leadership Team
28/09/2026
New appointments strengthen marketing, hospitality, category, and international commercial leadership as BrewDog advances long-term growth under Tilray Brands ELLON, Scotland and LONDON, Sept. 28, 2026 (GLOBE NEWSWIRE [...]
Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine
28/09/2026
– Pooled analysis of five clinical trials found no clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding traditional anthracycline limits – Independent Cleveland Clinic cardio-oncology [...]
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate
28/09/2026
– ARV-6723 is an investigational, oral PROTAC designed to degrade HPK1, a negative regulator of immune activation, in advanced solid tumors – NEW HAVEN, Conn., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: [...]
Pharmazz Completes Enrollment in 160-Patient Phase 4 Trial of Sovateltide in Acute Ischemic Stroke
28/09/2026
Enrollment completed in the double-blind, placebo-controlled Phase 4 study ( NCT05955326 ) of sovateltide (Tycamzzi®), with final study data expected in Q1 2027 Five sovateltide abstracts accepted at World Stroke [...]
Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer
28/09/2026
- Stable or increased weight was twice as common among pancreatic cancer patients in the atebimetinib + mGnP study, compared to those in a benchmark study - - Patients with stable or increased weight at three months had [...]
Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer
28/09/2026
Dr. Houvras brings over two decades of executive leadership across premier industry and academic research institutions in clinical development, translational medicine and immuno-oncology WALTHAM, Mass., Sept. 28, 2026 ( [...]
SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
28/09/2026
BARDA partnership accelerates development of SCY-247 as a potential therapy for the treatment and prevention of serious invasive fungal infections, addressing a critical public health need Non-dilutive funding for SCY- [...]
U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
28/09/2026
NDA submission completed following positive Phase 3 SELVA results; potential U.S. commercial launch in the first half of 2027, if approved QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and [...]
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
28/09/2026
New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenience FDA removal of the prior drug exposure limit provides greater dosing flexibility in future [...]
ORYZON Receives European Medicines Agency Approval to Initiate the HOPE-2 Phase II Study of Vafidemstat for the Treatment of Phelan-McDermid Syndrome (PMS)
28/09/2026
PMS is a severely disabling genetic disorder related to autism U.S. prevalence is estimated at approximately 1 in 7,300 people HOPE-2 is partially funded through Oryzon’s VANDAM project under Med4Cure, an Important [...]
Callio Therapeutics Appoints Chris Hassig, PhD, as Chief Scientific Officer
28/09/2026
Industry veteran brings more than two decades of oncology drug discovery leadership to advance Callio's dual-payload ADC pipeline SAN DIEGO and SEATTLE and SINGAPORE, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Callio [...]
NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes
28/09/2026
Following successful FDA Pre-IND meeting, NewcelX advances IND-enabling activities for NCEL-101 ZURICH, Sept. 28, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL), a regenerative medicine company developing stem- [...]
GuideAI Health Corp. and vRad Renew Data Exclusivity Agreement to Develop AI Models for the Detection and Characterization of Multiple Vascular Diseases
28/09/2026
Company holds exclusive access to imaging data from 2,100+ U.S. hospitals through its ongoing data partnership with vRad, the largest teleradiology provider in the United States BOSTON, Sept. 28, 2026 (GLOBE NEWSWIRE [...]
ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer
28/09/2026
Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for control, with response rates increasing to 63.6% versus 23.1% among patients with high CD47 expression and retained HER2- [...]
4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME
28/09/2026
4D-150 is advancing into Phase 3 development for DME, a second multi-billion-dollar retinal disease market with significant unmet need First patients have been enrolled in 4SIGHT global Phase 3 trial (N=514) evaluating [...]
Route 92 Medical Announces U.S. FDA Clearance for the FreeClimb® 46 Catheter with Tenzing® 4
28/09/2026
Expands Company’s Portfolio of Advanced Neurovascular Catheters to Support Treatment in Smaller and More Distal Anatomies WEST JORDAN, Utah, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held [...]
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
28/09/2026
Initial data expected in the first half of 2027 LEXINGTON, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing [...]

Pages